- Home
- / Elanco
Elanco
Stock Price
$12.5
2024-10-29
Market Capitalization
$6.2 B
2024-10-29
Revenue
$4.4 B
FY, 2023
Elanco Summary
Company Summary
- Overview
- Elanco is a company that develops, manufactures, and delivers products to prevent and treat disease in farm animals and pets. It offers vaccines, nutritional enzymes, antibiotics, parasiticides, and other products.
- Type
- Public
- Status
- Active
- Founded
- 1954
- HQ
- Greenfield, IN, US | view all locations
- Website
- https://www.elanco.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Ramiro Cabral, Executive Vice President, Elanco International
Fadi Debes, Senior Vice President, Corporate Controller and Financial Services
Dave Kinard, Executive Vice President, Human Resources, Corporate Affairs & Administration
Operating MetricsView all
Brands
200
5.3%
Q3, 2022
Countries
90
Q3, 2022
Sales Representatives
2.1K
6.3%
FY, 2021
LocationsView all
40 locations detected
Greenfield, IN HQ
United States
2500 Innovation Way/2710 Innovation Way
Buenos Aires, Provincia de Buenos Aires
Argentina
Colectora Este Ramal Pilar Manuel Alberti Suite 317
Macquarie Park, NSW
Australia
7 Eden Park Dr
Wien, Wien
Austria
Quartier Belvedere Central, Gertrude-Fröhlich-Sandner-Straße 3
Antwerpen, Vlaams Gewest
Belgium
Plantin en Moretuslei 1A
São Paulo, SP
Brazil
Av. das Nações Unidas, 14401, Torre Jequitibá
Elanco Financials
Summary Financials
- Revenue (Q3, 2024)
- $1.0B
- Gross profit (Q3, 2024)
- $538.0M
- Net income (Q3, 2024)
- $364.0M
- Cash (Q3, 2024)
- $490.0M
- Enterprise value
- $10.1B